US 5658724A
· Deluca et al.
· 1997
[cited by applicant]
US 5672344A
· Kelley et al.
· 1997
[cited by applicant]
US 5998174A
· Glorioso et al.
· 1999
[cited by applicant]
US 6106826A
· Brandt et al.
· 2000
[cited by applicant]
US 6719982B1
· Coffin et al.
· 2004
[cited by applicant]
US 6846670B2
· Schwartz et al.
· 2005
[cited by applicant]
US 6887490B1
· Jahoda et al.
· 2005
[cited by applicant]
US 7531167B2
· Glorioso et al.
· 2009
[cited by applicant]
US 9314505B2
· Wise et al.
· 2016
[cited by applicant]
US 9877990B2
· Krishnan et al.
· 2018
[cited by applicant]
US 20030082142A1
· Coffin et al.
· 2003
[cited by applicant]
US 20030190637A1
· Hovnanian
· 2003
[cited by examiner]
US 20040253606A1
· Aziz et al.
· 2004
[cited by applicant]
US 20050255085A1
· Fong
· 2005
[cited by examiner]
US 20070066552A1
· Clarke
· 2007
[cited by examiner]
US 20080299182A1
· Zhang
· 2008
[cited by applicant]
US 20100081707A1
· Ali et al.
· 2010
[cited by applicant]
US 20150352191A1
· South et al.
· 2015
[cited by applicant]
US 20180353614A1
· Peters
· 2018
[cited by applicant]
US 20190276845A1
· Glorioso et al.
· 2019
[cited by applicant]
US 20220273737A1
· Krishnan et al.
· 2022
[cited by applicant]
CN 102212559
· 2014
[cited by applicant]
EP 3377637
· 2018
[cited by applicant]
WO WO1999064094
· 1999
[cited by applicant]
WO WO2000040734
· 2000
[cited by applicant]
WO WO2013121202
· 2013
[cited by applicant]
WO WO2015009952
· 2015
[cited by applicant]
WO WO2015117021
· 2015
[cited by applicant]
WO WO2016191684
· 2016
[cited by applicant]
WO WO2017165806
· 2017
[cited by applicant]
WO WO2017165813
· 2017
[cited by applicant]
WO WO2017176336
· 2017
[cited by applicant]
WO WO2019200163
· 2019
[cited by applicant]
WO WO2019210219
· 2019
[cited by applicant]
WO WO2020006486
· 2020
[cited by applicant]
Goins WF, Lee KA, Cavalcoli JD, O'Malley ME, DeKosky ST, Fink DJ, Glorioso JC. Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. …
[cited by examiner]
Acland et al., “Gene therapy restores vision in a canine model of childhood blindness,” Nat Genet. (2001) 28(1):92-5.
[cited by applicant]
Aldawsari et al., “Progress in Topical siRNA Delivery Approaches for Skin Disorders,” Curr Pharm Des. (2015) 21(31): 4594-4605.
[cited by applicant]
Ali et al., “Gene therapy for inherited retinal degeneration,” Br J Ophthalmol. (1997) 81(9):795-801.
[cited by applicant]
Andtbacka et al., “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma,” J Clin Oncol. (2015) 33(25): 2780-2788.
[cited by applicant]
Armstrong, M. “Krystal gets more skin in the epidermolysis bullosa game.” Vantage. Mar. 5, 2019.
[cited by applicant]
Armstrong, M. “Krystal gets a flying start in epidermolysis bullosa gene therapy” Vantage. Oct. 17, 2018.
[cited by applicant]
Bastian et al., “Herpes simplex virus type 1 immediate-early protein ICP22 is required for VICE domain formation during productive viral infection.” J Viral. Mar. 2010;84(5):2384-94. doi: 10.1128/JVI.01686-09. Epub Dec.…
[cited by applicant]
Boehmer et al., “Herpes Virus Replication,” IUBMB Life (2003) 55(1):13-22.
[cited by applicant]
Brehm et al., “Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0,” Virology (1999) 256(2): 258-69.
[cited by applicant]
Burton et al., “Gene delivery using herpes simplex virus vectors.” DNA Cell Biol. Dec. 2002;21(12):915-936.
[cited by applicant]
Chamorro et al., “Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes”, Molecular Therapy—Nucleic Acids, vol. 5, 2016, pp. 1-13.
[cited by applicant]
Choate et al., “Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes,” Human Gene Therapy (1996) 7:2247-2253.
[cited by applicant]
Christiano AM. Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) [
[cited by applicant]
Clinicaltrials.gov. NCT03536143: Topical Bercolagene Telserpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa (GEM-1). May 24, 2018.
[cited by applicant]
Clinicaltrials.gov. NCT04047732: Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosonnal Recessive Congenital Ichthyosis (ARCI). Aug. 7, 2019.
[cited by applicant]
Clinicaltrials.gov. NCT04214002: The Natural History of Wounds in Patients with Dystrophic Epidermolysis Bullosa (DEB). Dec. 30, 2019.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for EP 16826873.8, dated Apr. 17, 2019, 7 pages.
[cited by applicant]
Periphagen, Complaint in
[cited by applicant]
Deluca et al., “Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4”, Journal Of Virology, (1985) 56(2): 558-570.
[cited by applicant]
Di et al., “Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome,” Hum Gene Ther Clin Dev. (2013) 24(4):182-190.
[cited by applicant]
Dingwell et al., “The Herpes Simplex Virus gE-gI Complex Facilitates Cell-to-Cell Spread and Binds to Components of Cell Junctions,” J Virol. (1998) 72(11): 8933-8942.
[cited by applicant]
Eming SA, Krieg T, Davidson JM. Gene therapy and wound healing. Clin Dermatol. Jan.-Feb. 2007;25(1):79-92.
[cited by applicant]
Eming et al., “Gene transfer in tissue repair: status, challenges and future directions,” Exp Opin Biol Ther (2004) 4(9):1373-1386.
[cited by applicant]
Farasat et al., “Novel transglutaminase-1 mutations and genotype-phenotype investigations of 104 patients with autosomal recessive congenital ichthyosis in the USA,” J Med Genet (2009) 46(2):103-111.
[cited by applicant]
Final Office Action received for U.S Appl. No. 15/393,151, mailed on Aug. 31, 2017, 13 pages.
[cited by applicant]
Fink et al., “Gene therapy for pain: Results of a Phase I clinical trial,” Ann Neurol (2011) 70(2):207-212.
[cited by applicant]
Fraefel et al., “In vivo gene transfer to the rat retina using herpes simplex virus type 1 (HSV-1)-based amplicon vectors,” Gene Ther. (2005) 12(16):1283-8.
[cited by applicant]
Geller et al., “An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology,” Proc Natl Acad Sci U S A. (1990) 87(22): 8…
[cited by applicant]
Georgiadis et al., “Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB”, Journal of Investigative Dermatology, (2016) 136: 284-292.
[cited by applicant]
Glorioso JC. “Herpes simplex viral vectors: late bloomers with big potential.” Hum Gene Ther. (2014) 25(2): 83-91.
[cited by applicant]
Goins et al. “Engineering HSV-1 Vectors for Gene Therapy,” Methods Mol Biol (2014) 1144: 63-79.
[cited by applicant]
Goins et al. “Generation of replication-competent and -defective HSV vectors,” Cold Spring Harb Protoc. May 1, 2011;2011(5): 512-519; pdb.prot5615.
[cited by applicant]
Gorell et al., “Gene therapy for skin diseases,” Cold Spring Harb Perspect Med (2014) 4:a015149.
[cited by applicant]
Goto et al., “Fibroblasts Show More Potential as Target Cells than Keratinocytes in COL7A1 Gene Therapy of Dystrophic Epidermolysis Bullosa”, Journal of Investigative Dermatology, (2006) 126: 766-772.
[cited by applicant]
Grant, Kyle, “Production and Purification of Highly Replication Defective Hsv-1 Based Gene Therapy Vectors”, Doctoral Dissertation, University of Pittsburgh, 2008, 137 pages.
[cited by applicant]
Gurevich et al. 759 “Successful in vivo col. 7A1 gene delivery and correction of recessive dystrophic epidermolysis bullosa (RDEB) skin using an off the shelf HSV-1 vector (KB103).” J Invest Derm. vol. 138, Iss. 5 Supp.…
[cited by applicant]
Heikkinen et al., “Diremerization of human lysyl hydroxylase 3 (LH3) is mediated by the amino acids 541 547,” Matrix Biology (2010) 30(1):27-33.
[cited by applicant]
Hennig et al., “HEK293-based production platform for y-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA”. Hum Gene Ther Clin Dev. Dec. 2014;25(4):218-28.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/068974, mailed on Oct. 18, 2018, 11 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/068974, mailed on May 18, 2017, 18 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US2016/068974, mailed on Mar. 27, 2017, 8 pages.
[cited by applicant]
Kim et al., “Microneedles for Drug and Vaccine Delivery”, Advanced Drug Delivery Reviews, vol. 64, 2012, pp. 1547-1568.
[cited by applicant]
Kohlhapp et al., Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy, Clinical Cancer Research (2015) 22(5):1048-1054.
[cited by applicant]
Kopecki et al., “Commentary: New advances in the development of therapies for treating inherited skin fragility disorders,” Wound Practice and Research (2015) 23(4): 184, Dec. 5, 2015.
[cited by applicant]
Krisky et al., “Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons,” Gene Ther. (1998) 5(12):1593-603.
[cited by applicant]
Krisky et al., “Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications,” Gene Ther (1998) 5(110):1517-1530.
[cited by applicant]
Krystal Biotech, Inc. “Krystal Biotech Announces Settlement with PeriphaGen, Inc.” Mar. 15, 2022, https://ir.krystalbio.com/node/8481/pdf. (Year: 2022).
[cited by applicant]
Lachmann, R. “Herpes simplex virus-based vectors,” Int J Exp Pathol. (2004) 85(4): 177-190.
[cited by applicant]
Lewin et al., “Gene therapy for autosomal dominant disorders of keratin,” J Investig Dermatol Symp Proc. (2005) 10(1): 47-61.
[cited by applicant]
Liu et al., “Herpes simplex virus mediated gene transfer to primate ocular tissues,” Exp Eye Res. (1999) 69(4):385-95.
[cited by applicant]
Lu et al., “Topical Application of Viral Vectors for Epidermal Gene Transfer”, J Invest Dermatol. (1997) 108(5): 803-808.
[cited by applicant]
Ma et al., “Efficacy of Herpes Simplex Virus Vector Encoding V the Human Preproenkephalin Gene for Treatment of Facial Pain in Mice,” J aral Facial Pain Headachce (2016) 30(1):42-50.
[cited by applicant]
Marconi et al., “HSV as a Vector in Vaccine Development and Gene Therapy.” In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. 30 pages.
[cited by applicant]
Marconi et al., “Replication-defective herpes simplex virus vectors for gene transfer in vivo,” Proc Natl Acad Sci USA (1996) 93:11319-11320.
[cited by applicant]
Mayr et al., “Gene Therapy for the COL7A1 Gene”, Chapter 23, Intech, 2013, pp. 561-589.
[cited by applicant]
McGowan et al., “Keratin 17 n ull mice exhibit age- and strain-dependent alopecia,” Genes & Dev (2002) 16:1412-1422.
[cited by applicant]
Messmer et al., “Ocular manifestations of keratitis-ichthyosis-deafness (KID) syndrome,” Ophthalmology. (2005) 112(2):e1-6.
[cited by applicant]
Miezeiewski et al., “Role of adherens junction proteins in differential herpes simplex virus type 2 infectivity in communication-competent and -deficient cell lines,” Intervirology. (2012) 55(6): 465-474.
[cited by applicant]
Miyagawa et al., “Herpes simplex viral-vector design for efficient transfuction of nonneuronal cells without cytotoxcity,” Proc Natl Acad Sci USA (2015) 112(13):E1632-E1641.
[cited by applicant]
Miyagawa et al., “Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes,” Mol Ther Methods Clin Dev. (2017) 6: 79-90.
[cited by applicant]
Ng et al., “Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa”, Cancer Research, vol. 72, No. 14, Jul. 15, 20…
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 15/393,151, mailed on Apr. 14, 2017, 13 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 15/851,488, mailed on May 14, 2018, 10 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/177,153, mailed on May 9, 2019, 13 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 15/393,151, mailed on Dec. 6, 2017, 11 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 15/851,488, mailed on Oct. 29, 2018, 11 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/177,153, mailed on Aug. 30, 2019, 10 pages.
[cited by applicant]
Ortiz-Urda et al., “Injection of Genetically Engineered Fibroblasts Corrects Regenerated Human Epidermolysis Bullosa Skin Tissue”, The Journal of Clinical Investigation, vol. 111, No. 2, Jan. 2003, pp. 251-255.
[cited by applicant]
Peek et al., “Herpes simplex virus infection of the human eye induces a compartmentalized virus-specific B cell response,” J Infect Dis. (2002) 186(11):1539-46.
[cited by applicant]
Pepose et al., “Herpes simplex viral vectors for therapeutic gene delivery to ocular tissues. Recent breakthroughs in the molecular genetics of ocular diseases,” Invest Ophthalmol Vis Sci. (1994) 35(6):2662-6.
[cited by applicant]
[cited by applicant]
Periphagen, Krystal Biotech Inc., Answer and Counterclaim in
[cited by applicant]
Rahn et al., “Invasion of Herpes Simplex Virus Type 1 into Murine Epidermis: An Ex Vivo Infection Study,” J Invest Dermatol. (2015) 135(12): 3009-3016.
[cited by applicant]
Sabater et al., “Topical beremagene geperpavec (B-VEC) for the treatment of recurrent cicatrizing conjunctivitis in a patient with dystrophic epidermolysis bullosa,” ARVO Annual Meeting, New Orleans, LA, USA, Apr. 23-27…
[cited by applicant]
Salam A. “Krystal's KB103 splits experts' thoughts on potential for HSV-1 risk in dystrophic epidermolysis bullosa patients, but final Phase I/II efficacy assured.” Nov. 7, 2018. Biopharm Insight.
[cited by applicant]
Salameh et al., “Early events in herpes simplex virus lifecycle with implications for an infection of lifetime,” Open Virol J. (2012) 6:1-6.
[cited by applicant]
Salmon-Ehr et al., “Implication of Interleukin-4 in Wound Healing”, Laboratory Investigation, vol. 80, No. 8, Aug. 2000, pp. 1337-1343.
[cited by applicant]
Samaniego et al., “Persistence and Expression of the Herpes Simplex Virus Genome in the Absence of Immediate-Early Proteins”, Journal of Virology, (1998) 72(4); 3307-3320.
[cited by applicant]
Samaniego et al., “The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27,” J Virol. (1997) 71(6): 4614-4625.
[cited by applicant]
Sankar et al., “A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhersion in ewing sarcoma,” Molecular and Cellular Biology (2013) 33(22):4448-4460.
[cited by applicant]
Shen et al., “Herpes simplex virus 1 (HSV-1) for cancer treatment,” Cancer Gene Therapy (2006) 13: 975-992.
[cited by applicant]
Silva et al., “Herpes Virus Amplicon Vectors”, Viruses, vol. 1, 2009, pp. 594-629.
[cited by applicant]
Siprashvili et al., “Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue,” Hum Gene Ther. Oct. 2010;21(10):1299-310.
[cited by applicant]
Spencer et al., “HSV-1 vector-delivered FGF2 to the retina is neuroprotective but does not preserve functional responses,” Mol Ther. (2001) 3(5 Pt 1):746-56.
[cited by applicant]
Stow et al., Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. J Gen Viral. Dec. 1986;67 (Pt 12):2571-85.
[cited by applicant]
Sufiawati et al., “HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread,” PLoS One. (2014) 9(2): e88803.
[cited by applicant]
Sufiawati et al., “HIV-induced matrix metalloproteinase-9 activation through mitogen-activated protein kinase signalling promotes HSV-1 cell-to-cell spread in oral epithelial cells,” J Gen Virol. (2018) 99(7): 937-947.
[cited by applicant]
Theopold et al., “A novel replication-defective HSV-1 vector for regulatable gene delivery to wounds,” Journal of the American College of Surgeons (2004) 199(3):57-58.
[cited by applicant]
Uitto et al., “Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015”, Journal of Investigative Dermatology, vol. 136, 2016, pp. 352-358.
[cited by applicant]
Wang et al., “Comparative Effectiveness of Antinociceptive Gene Therapies in Animal Models of Diabetic Neuropathic Pain”, Gene Therapy, vol. 20, 2013, pp. 742-750.
[cited by applicant]
Wang et al., “Updates on Gene Therapy for Diabetic Retinopathy,” Curr Diab Rep. (2020) 20(7):22.
[cited by applicant]
Watanabe et al., “Properties of a Herpes Simplex Virus Multiple Immediate-early Gene-Deleted Recombinant as a Vaccine Vector”, Virology, vol. 357, 2007, pp. 186-198.
[cited by applicant]
Watt et al., “Lysyl Hydroxylase 3 Localizes to Epidermal Basement Membrane and Is Reduced in Patients with Recessive Dystrophic Epidermolysis Bullosa”, Plos One, (2015) 10(9): e0137639.
[cited by applicant]
Weiss et al., “The Role of Interleukin 10 in the Pathogenesis and Potential Treatment of Skin Diseases”, Journal of the American Academy of Dermatology, vol. 50, No. 5, May 2004, pp. 657-675.
[cited by applicant]
White et al., “Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery,” Cancer Gene Ther. May 2011;18(5):358-69. doi: 10.1…
[cited by applicant]
Wolfe et al., “Engineering Herpes Simplex Viral Vectors for Therapeutic Gene Transfer”, Chapter 6, Gene and Cell Therapy, 2004, pp. 103-129.
[cited by applicant]
Woodley et al., “Normal and Gene-Corrected Dystrophic Epidermolysis Bullosa Fibroblasts Alone Can Produce Type VII Collagen at the Basement Membrane Zone”, The Journal of Investigative Dermatology, vol. 121, No. 5, Nov.…
[cited by applicant]
Woodley, et al., “Intradermal Injection of Lentiviral Vectors Corrects Regenerated Human Dystrophic Epidermolysis Bullosa Skin Tissue in Vivo”, Molecular Therapy, vol. 10, No. 2, Aug. 2004, pp. 318-326.
[cited by applicant]
Wu et al., “Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22,” J Virol. (1996) 70(9): 6358-6369.
[cited by applicant]
Saeki et al., “Improved Helper Virus-Free Packaging System for HSV Amplicon Vectors Using an ICP27-Deleted, Oversized HSV-1 Dna in a Bacterial Artificial Chromosome.” Molecular Therapy. 2001. vol. 3, No. 4, pp. 591-601.
[cited by applicant]
Titeux et al., “Gene therapeutics strategies for blistering skin diseases.” Drug Discovery Today: Therapeutic Strategies. 2006. vol. 3, No. 1, pp. 87-92.
[cited by applicant]
Office Action from related Application KR 10-2018-7030112, dated Jan. 24, 2024.
[cited by applicant]